ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 903,29
0,23%
DAX
17 932,17
-1,10%
Brent Oil
83,54
-2,74%
Bitcoin
57 923,14
-4,41%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Beam Therapeutics Inc (BEAM)

  7. Beam Therapeutics Inc (BEAM) Actualités

BEAM Beam Therapeutics Inc

21,74
0,52 (2,45%)
Après les heures de négociation
Dernière mise à jour : 23:30:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Beam Therapeutics Inc BEAM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,52 2,45% 21,74 23:30:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
21,27 21,01 22,83 21,74 21,22
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
26/3/202411:30GLOBEBeam Therapeutics Announces Clearance of Clinical Trial..
28/2/202412:30GLOBEBeam Therapeutics to Participate in Upcoming March 2024..
27/2/202413:40EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202413:22EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202412:43EDGAR2Form 8-K - Current report
27/2/202412:30GLOBEBeam Therapeutics Reports Fourth Quarter and Year-End 2023..
05/2/202412:30GLOBEBeam Therapeutics to Participate in the Guggenheim..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202422:47EDGAR2Form 144 - Report of proposed sale of securities
08/1/202412:55EDGAR2Form 8-K - Current report
08/1/202412:30GLOBEBeam Therapeutics Highlights Progress Across Base Editing..
05/1/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202412:30GLOBEBeam Therapeutics to Present at the 42nd Annual J.P. Morgan..
14/12/202322:05EDGAR2Form 8-K - Current report
14/12/202312:30GLOBEBeam Therapeutics Appoints Biotech Executive Christi Shaw to..
20/11/202322:20EDGAR2Form 144 - Report of proposed sale of securities
08/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202313:00EDGAR2Form 8-K - Current report
08/11/202312:30GLOBEBeam Therapeutics Reports Pipeline and Business Updates and..
01/11/202321:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/10/202311:59DJNBeam Therapeutics to Sell Rights in Verve Licensing Deal to..
31/10/202311:44EDGAR2Form 8-K - Current report
31/10/202311:00GLOBEBeam Announces Agreement for Lilly to Acquire Beam’s Opt-In..
30/10/202321:41EDGAR2Form 144 - Report of proposed sale of securities
25/10/202312:30GLOBEBeam Therapeutics Presents Preclinical Data Highlighting..
24/10/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202314:50EDGAR2Form 8-K - Current report
19/10/202314:45GLOBEBeam Therapeutics Announces Portfolio Prioritization and..
04/10/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/9/202316:00GLOBEBeam Therapeutics Presents Preclinical Data Highlighting..
05/9/202312:30GLOBEBeam Therapeutics Announces First Patient Dosed in Phase 1/2..
31/8/202312:30GLOBEBeam Therapeutics to Participate in Upcoming September..
09/8/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:11EDGAR2Form 8-K - Current report
08/8/202312:30GLOBEBeam Therapeutics Reports Pipeline Updates and Second..
26/7/202300:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/7/202300:31EDGAR2Form 144 - Report of proposed sale of securities
17/5/202312:30GLOBEBeam Therapeutics to Participate in Upcoming May Investor..
11/5/202312:30GLOBEBeam Therapeutics to Participate in RBC Capital Markets 2023..
10/5/202312:30GLOBEBeam Therapeutics Reports Pipeline Updates and First Quarter..

Dernières Valeurs Consultées

NASDAQ
BEAM
Beam Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés